FRANKFURT (Reuters) - Pfizer's German development partner BioNTech on Thursday joined other leading COVID-19 vaccine developers in ruling out participation in British plans to test experimental inoculations by deliberately infecting trial volunteers.
"BioNTech's vaccine candidate is not part of this study," a spokeswoman said.
Britain is planning to host so-called "challenge trials", the Financial Times cited people involved in the project as saying. Britain said it was working with partners on the potential for human challenge trials without commenting on a specific plan. [nL3N2GK3AK]
AstraZeneca and Sanofi and Moderna, among the leading vaccine developers, have said their vaccine candidates were not involved in the programme.
U.S. biotech firm Inovio Pharmaceuticals also said it was not involved while Johnson & Johnson said it was evaluating the potential benefit of a human challenge trial but would not comment on the British plans.
The World Health Organisation was not involved in such studies, a spokesman said on Thursday.
In a paper https://apps.who.int/iris/bitstream/handle/10665/331976/WHO-2019-nCoV-Ethics_criteria-2020.1-eng.pdf?ua=1 published in May, the WHO said challenge trials could be risky even if limited to young, healthy adults because too little is known about how COVID-19 progresses and there are no specific treatments apart from Gilead's
U.S.-based advocacy group 1Day Sooner, which is lining up volunteers and is lobbying for challenge trials, in a media briefing on Thursday said it did not have confirmation about which vaccines had been eyed for testing in Britain.
Leading vaccine makers have each recruited tens of thousands of volunteers in late-stage trials that rely on accidental infections to yield results on efficacy.
(Additional reporting by Trisha Roy and Sri Kalyani Manojna Maddipatla; editing by Thomas Seythal and Alexandra Hudson)
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU